Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMA COMPOUND vs CEPHULAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.
Relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: management of muscle spasms, tension headaches
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy) including the prevention and treatment of coma
1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.
30-45 m L (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 m L orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 m L in 700 m L of water or saline as retention enema for 30-60 min every 4-6 hours.
Carisoprodol: approximately 2-4 hours in adults with normal renal function. Meprobamate: approximately 10-12 hours. The prolonged half-life of meprobamate contributes to accumulation with repeated dosing, especially in elderly or renally impaired patients, leading to increased risk of sedation and dependence.
Terminal elimination half-life is 7-10 hours (renal impairment: prolonged); systemic absorption is minimal (<3%) after oral administration, so half-life reflects clearance of absorbed fraction.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite); aspirin is hydrolyzed to salicylic acid via esterases in the liver and plasma.
Not absorbed; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to low molecular weight organic acids.
Carisoprodol and its active metabolite meprobamate are primarily excreted renally. Approximately 60% of a dose is eliminated as unchanged carisoprodol and meprobamate in urine, with the remainder as various hydroxylated metabolites. Less than 1% is eliminated in feces. Meprobamate undergoes hepatic metabolism, and about 10-20% is excreted unchanged in urine.
Primarily renal (20-30% as unchanged drug) and fecal (up to 70% as unmetabolized drug via biliary elimination; following gastric acid-mediated degradation, only 5-10% reaches urine as intact lactulose; hepatic metabolism is negligible).
Carisoprodol: approximately 60% bound to plasma proteins, primarily albumin. Meprobamate: approximately 15-25% bound to plasma proteins.
Negligible (<5%): lactulose does not bind significantly to albumin or other plasma proteins due to its hydrophilic nature.
Carisoprodol: Vd approximately 0.5-1.0 L/kg, indicating distribution into total body water and some tissue binding. Meprobamate: Vd about 0.7 L/kg.
0.5-1.0 L/kg (estimated from systemic absorption studies; limited data due to minimal absorption; reflects distribution largely into extracellular water).
Oral: Carisoprodol is well absorbed with bioavailability >90%. The absorption rate may be slightly reduced with food, but extent is not significantly affected.
Oral: <3% (due to poor absorption and extensive metabolism by colonic bacteria; most of the drug remains in the gut lumen). Rectal: similar to oral, as systemic absorption is minimal.
Cr Cl <30 m L/min: avoid use due to aspirin component; Cr Cl 30-50 m L/min: reduce dose or extend interval; monitor for carisoprodol accumulation.
No dose adjustment required for renal impairment as lactulose is minimally absorbed and primarily acts locally in the colon.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not specifically adjusted based on Child-Pugh score; dose is titrated to achieve desired stool frequency; caution in severe hepatic impairment due to risk of electrolyte disturbances.
Not recommended for children under 12 years; safety and efficacy not established.
Infants: 2.5-10 m L/day in divided doses; older children: 10-25 m L/day; adolescents: 15-30 m L/day; all for constipation; for hepatic encephalopathy, doses as low as 5-10 m L 3-4 times daily with dose adjusted to produce 2-3 soft stools per day.
Initiate at lowest dose (1 tablet); avoid use in patients with Cr Cl <30 m L/min; monitor for CNS depression and bleeding risk.
Initiate at lower end of dosing range (15-30 m L/day) due to increased risk of dehydration and electrolyte imbalance; monitor for diarrhea and adjust accordingly.
No FDA black box warning.
None
Dependence and withdrawal: Carisoprodol can cause dependence, abuse, and withdrawal symptoms after prolonged use,Sedation: May impair mental or physical abilities; caution with driving or operating machinery,Bleeding risk: Aspirin component increases risk of bleeding, especially with alcohol, anticoagulants, or existing bleeding disorders,Hypersensitivity: Allergic reactions including anaphylaxis can occur
Electrolyte imbalance with prolonged use, especially in debilitated patients,Diarrhea may cause fluid and electrolyte loss,Galactose intolerance (contraindicated in patients requiring low galactose diet due to lactose content in some preparations),Monitor serum electrolytes in patients receiving high doses for hepatic encephalopathy
History of acute intermittent porphyria,Hypersensitivity to carisoprodol, meprobamate, aspirin, or any component,Severe hepatic or renal impairment,Gastrointestinal bleeding or peptic ulcer disease (active),Children with viral infections (Reye's syndrome risk),Third trimester of pregnancy (aspirin component)
Patients requiring a low-galactose diet (lactulose contains galactose and lactose),Intestinal obstruction,Suspected gastrointestinal obstruction or perforation
Avoid alcohol. Aspirin may cause gastrointestinal irritation; take with food or a full glass of water to reduce risk. Avoid high-dose vitamin C or acidic foods that may increase aspirin absorption and toxicity.
No specific food interactions. Avoid concurrent use with other laxatives unless directed. High-fiber foods may enhance effect; ensure adequate fluid intake.
Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin component (if present in compound) is associated with increased risk of neural tube defects and fetal hemorrhage if used in third trimester. Avoid use during pregnancy unless benefit outweighs risk.
Lactulose (CEPHULAC) is not absorbed systemically; therefore, fetal exposure is negligible. Animal studies have not shown teratogenic effects. In clinical practice, no fetal risks have been identified in any trimester.
Carisoprodol and its active metabolite meprobamate are excreted in breast milk. M/P ratio not well established. Concentrations may reach clinical significance. Potential for infant sedation, hypotonia, or withdrawal. Avoid breastfeeding while on this medication.
Lactulose is not excreted into breast milk due to minimal systemic absorption. It is considered compatible with breastfeeding. M/P ratio: Not applicable (negligible absorption).
No established dosing adjustments for pregnancy. Due to increased renal clearance during pregnancy, consider that standard doses may be less effective. However, lack of safety data generally contraindicates use. If absolutely necessary, use lowest effective dose for shortest duration.
No dose adjustment required. Pharmacokinetics are unchanged in pregnancy due to lack of systemic absorption. Standard dosing of 15-30 m L (10-20 g) once daily, up to 60 m L/day in divided doses, is appropriate.
Soma Compound contains carisoprodol (a centrally acting muscle relaxant) and aspirin (an NSAID). Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with a history of substance abuse, porphyria, or G6PD deficiency. Monitor for signs of CNS depression, especially when combined with alcohol or other sedatives. Aspirin increases bleeding risk; avoid in patients with bleeding disorders or those on anticoagulants. Do not use in children or adolescents with viral infections due to risk of Reye's syndrome.
Cephulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. In hepatic encephalopathy, titrate to produce 2-3 soft stools per day. Monitor serum electrolytes, especially in elderly or renal impairment. Onset of action for constipation may be 24-48 hours. Do not confuse with other lactose-containing products.
Take exactly as prescribed; do not increase dose or frequency.,Do not drive or operate heavy machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report any signs of bleeding (bruising, black stools, blood in urine) or allergic reactions (rash, swelling, difficulty breathing).,Do not use in children or teenagers with chickenpox or flu symptoms due to risk of Reye's syndrome.,This medication may be habit-forming; do not stop abruptly without consulting your doctor.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; may take 24-48 hours to produce a bowel movement.,For hepatic encephalopathy, maintain 2-3 soft stools daily; do not skip doses.,May cause bloating, gas, or cramping initially; usually resolves.,Do not take other laxatives without consulting your doctor.,Report severe diarrhea, vomiting, or muscle cramps to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMA COMPOUND vs CEPHULAC, answered by our medical review team.
SOMA COMPOUND is a Skeletal Muscle Relaxant Combination that works by Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.. CEPHULAC is a Laxative that works by Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMA COMPOUND and CEPHULAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMA COMPOUND is: 1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.. The standard adult dose of CEPHULAC is: 30-45 m L (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 m L orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 m L in 700 m L of water or saline as retention enema for 30-60 min every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMA COMPOUND and CEPHULAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMA COMPOUND is classified as Category C. Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin com. CEPHULAC is classified as Category C. Lactulose (CEPHULAC) is not absorbed systemically; therefore, fetal exposure is negligible. Animal studies have not shown teratogenic effects. In clinical practice, no fetal risks . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.